Daily life cardiac ischaemia. Should it be treated?
Related Experiment Videos
1Department of Medicine, University of Florida Health Sciences Center, Gainesville, USA.
Insights
Daily life cardiac ischemia, often asymptomatic, signifies myocardial hypoxia during normal activities. Ambulatory ECG monitoring aids detection, and antianginal medications may reduce its occurrence and severity.
Area of Science:
- Cardiology
- Internal Medicine
Background:
- Daily life cardiac ischemia involves reversible myocardial hypoxia during routine activities.
- Most episodes are asymptomatic but linked to adverse cardiovascular outcomes.
- Distinguishing silent from symptomatic ischemia is clinically impractical due to shared risks.
Purpose of the Study:
- To review the detection, management, and therapeutic strategies for daily life cardiac ischemia.
- To highlight the importance of objective testing in evaluating treatment efficacy.
Main Methods:
- Ambulatory electrocardiogram (ECG) monitoring is the primary diagnostic tool.
- Exercise treadmill tests can also be utilized for detection.
- Review of current antianginal medications and revascularization strategies.
Main Results:
- Daily life cardiac ischemia is best detected via ambulatory ECG monitoring.
- Standard antianginal drugs (nitrates, beta-blockers, calcium antagonists, antiplatelets) appear effective in reducing ischemia.
- Therapeutic goal is to eliminate all ischemic episodes to prevent future cardiac events.
Conclusions:
- Medical therapy and revascularization are crucial for managing daily life cardiac ischemia.
- Follow-up objective testing is essential to document therapeutic regimen efficacy.
- Diagnosis and management strategies are evolving, influenced by future research and economic factors.
Abstract:
Daily life cardiac ischaemia is defined as reversible myocardial cellular hypoxia that occurs during activities of daily living, without artificial provocation. Most of these daily life ischaemic episodes are not associated with symptoms. However, it is not practical to distinguish silent versus symptomatic daily life ischaemia as both are associated with haemodynamic abnormalities and future adverse outcomes. Daily life cardiac ischaemia is best detected using ambulatory electrocardiogram (ECG) monitoring; however, there are other diagnostic tools (e.g. exercise treadmill) that can be used. Once detected, the optimal therapy for daily life myocardial ischaemia has yet to be identified. However, it does appear that usual antianginal medications including nitrates, beta-blockers, calcium antagonists and antiplatelet drugs are effective in reducing the incidence and severity of daily life myocardial ischaemia. Medical therapy and revascularisation should be utilised to obliterate all episodes of daily life cardiac ischaemia to prevent future cardiac events. Moreover, the efficacy of the chosen therapeutic regimen for each patient should be documented with follow-up objective testing. The diagnosis and management of daily life myocardial ischaemia is continually evolving. Future research as well as economic considerations will shape future management strategies.